Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model
2001
Optimal Timing and Dosage of Chemotherapy for Prostate Cancer
publication
Evidence: moderate
Author Information
Author(s): Miyake H, Hara S, Arakawa S, Kamidono S, Hara I
Primary Institution: Kobe University School of Medicine
Hypothesis
Can the efficacy of chemotherapy be enhanced by changing the regimen in combination with androgen withdrawal?
Conclusion
The study suggests that simultaneous chemotherapy and androgen withdrawal may be the best approach for treating advanced prostate cancer.
Supporting Evidence
- Mitoxantrone showed a synergistic effect on inducing apoptosis in LNCaP cells when combined with androgen withdrawal.
- Simultaneous treatment with mitoxantrone and castration significantly inhibited LNCaP tumor growth.
- Apoptotic cell death was extensively induced in tumors treated with simultaneous castration and mitoxantrone.
Takeaway
This study found that giving chemotherapy and hormone treatment at the same time works better for prostate cancer than doing them separately.
Methodology
The study evaluated the effects of timing and dosage of chemotherapy in combination with androgen withdrawal in a human prostate cancer model using athymic nude mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website